Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
An image of Dr John Day.

“It’s my pleasure to welcome Dr John Day, who brings decades of experience working and teaching in the neuromuscular disease space, to PepGen’s Scientific Advisory Board,” said James McArthur, PhD, President and Chief Executive Officer of PepGen. 

Throughout his career, Dr Day has investigated the multisystemic effects of myotonic dystrophy type 1 and 2 and other genetic disorders and has more than 30 years of experience directing clinical trials of oligonucleotide and other novel treatments that correct genetic disorders of nerves and muscles.

After completing his neurology and neuromuscular training at the University of California, San Francisco, Dr Day was recruited to the University of Minnesota, where, as Professor of Neurology, Pediatrics and Genetics, he founded and directed the Paul and Sheila Wellstone Muscular Dystrophy Center.

In 2011, he was recruited to Stanford to establish a comprehensive Division of Neuromuscular Medicine. He is an advisor for multiple organizations in the neuromuscular disease space, including the National Advisory Committee for the Myotonic Dystrophy Foundation, and is a member of the Society for Neuroscience, the American Academy of Neurology, and the World Muscle Society, among others.

Dr Day received his M.D. from the University of Minnesota and earned his PhD in neuroscience from the Albert Einstein College of Medicine, where he studied synaptic physiology and plasticity.

Click here to read the full article